Kyverna Therapeutics News and Activities

View the org chart displaying its 34 main executives

Most searched biographies at Kyverna Therapeutics

• Warner Biddle, Chief Executive Officer and Director
• Mert Aktar, Director
• Sravan Emany, Director

Popular executive movements at Kyverna Therapeutics

• Nadia Dac has joined the company as Chief Commercial Officer  (posted on May 5 2026).
• Andrew Miller has joined the company as Director  (posted on February 24 2026).
• Sravan Emany has joined the company as Director  (posted on February 24 2026).

Click here to view some more movements at Kyverna Therapeutics

Create your alert
to follow the executive moves at Kyverna Therapeutics.

Kyverna Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Kyverna Therapeutics

• News Releases | Kyverna Therapeutics
• Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy | Kyverna Therapeutics
• Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Kyverna Therapeutics
• Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Announces First Publication of Ingenui-T, a Novel CAR T-Cell Vein-to-Vein Manufacturing Process | Kyverna Therapeutics
• Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis | Kyverna Therapeutics
• Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases | Kyverna Therapeutics
• View more press releases Close

Social media about Kyverna Therapeutics

• Kyverna Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kyverna Therapeutics on LinkedIn, X (Twitter) & YouTube